Back to top

Depomed, Inc. (DEPO)

Read MoreHide Full Article

We have been bullish on Depomed (DEPO) in the past, and we remain enthusiastic about the development pipeline.

PHN candidate DM-1796 is currently under review at the U.S. FDA. Acceptance of the filing triggers a $10 million milestone payment from partner Abbott Labs to Depomed. In the meantime, Depomed is looking to begin a confirmatory phase III program with Serada any day now.

Over the long-run, we think it would be wise to average down or establish a position at this level. Our target is $7 based on discounted future EPS.




Normally $25 each - click below to receive one report FREE:



More from Zacks Bull of the Day

You May Like